Department of Orthopaedics & Traumatology, Taipei Veterans General Hospital, Taiwan.
Department of Orthopaedics, Therapeutical and Research Center of Musculoskeletal Tumor, Taipei Veterans General Hospital, Taiwan.
Clin Orthop Relat Res. 2018 Apr;476(4):877-889. doi: 10.1007/s11999.0000000000000022.
Immediately recycling the resected bone segment in a biologic limb salvage reconstruction is an option after wide resection of bone. Intraoperative extracorporeal irradiation and freezing are the two major tumor-killing techniques applied on the fresh tumor-bearing autografts. However, graft-derived tumor recurrence and complications are concerns affecting graft survival.
QUESTIONS/PURPOSES: We therefore asked: (1) Is there a difference in the proportion of patients achieving union by 18 months after surgery between the groups with extracorporeal-irradiated autografts and frozen-treated autografts? (2) Is there any difference in the frequency of graft-related complications for patients receiving either an extracorporeal-irradiated or a frozen-treated autograft? (3) Is there a difference between the techniques in terms of graft-derived recurrence? (4) Are there differences in failure-free grafts, and limb and overall survivorship between autografts treated by extracorporeal irradiation or by freezing?
During the study period we treated a total of 333 patients with high-grade osteosarcoma. One hundred sixty-nine patients were excluded. Overall, 79 of the enrolled 164 patients received recycled autografts treated with extracorporeal irradiation whereas the other 85 received frozen-treated autografts. The mean followup was 82 ± 54 months for the extracorporeal irradiation group and 70 ± 25 months for the frozen autograft group, and one patient was lost to followup. Complications and graft failure (revision required for primary graft removal) were characterized by adapting the International Society of Limb Society (ISOLS) system modified for inclusion of biologic and expandable reconstruction. The primary study endpoints were the proportion of patients in each group who achieved radiographic union, and had an ISOLS grade of fair or good host graft fusion at 6, 9, 12, and 18 months after surgery. Five-year survival data for graft failure and limb amputation were analyzed by a cumulative incidence function regression model whereas the Kaplan-Meier function was used to test the 5-year overall survival rate between the two techniques.
With the numbers available, no differences were found in the accumulated proportion of patients achieving union between the groups at 6, 9, 12, and 18 months. Radiographic evaluation did not show differences in the average scores of compared criteria. However in the subchondral bone subcriterion, more patients receiving frozen-treated autografts had higher scores (p = 0.03). Complications leading to a second surgery were not different between extracorporeal irradiation and frozen autografts in aspects of soft tissue failure (Type 1B), nonunion (Type 2B), structural failure (Type 3A and Type 3B), or infection (Type 4A and Type 4B). No graft-originating tumor recurrence was found and there was no difference in Type 5A tumor progression originating from soft tissue in the groups (odds ratio, 0.8; 95% CI, 0.3-2.1; p = 0.7). Neither group showed a difference in the cumulative incidence for graft failure and limb amputation. Five-year overall survival rates were 83% and 84% (p = 0.69) for extracorporeal-irradiated and frozen autografts respectively. A decrease in survivorship was seen at 50 to 100 months after surgery for the extracorporeal irradiation group.
We segregated the ISOLS criteria evaluating the graft-mediated tumor progression into host- or graft-derived complications (Types 5B and 5C) in this study. With the available data, there was no difference in the incidence of tumor recurrence derived from irradiation- or frozen-treated autografts. Ongoing evaluations comparing 10-year survivorship for both groups will be helpful to elucidate the possible difference found after 100 months.
III, therapeutic study.
在广泛切除骨后,将切除的骨段立即在生物肢体 salvage 重建中回收是一种选择。术中体外照射和冷冻是应用于新鲜含肿瘤移植物的两种主要肿瘤杀伤技术。然而,移植物来源的肿瘤复发和并发症是影响移植物存活的关注点。
问题/目的:因此我们提出了以下问题:(1)在接受体外照射自体移植物和冷冻处理自体移植物的患者中,术后 18 个月时通过手术达到愈合的患者比例是否存在差异?(2)接受体外照射或冷冻处理自体移植物的患者中,与移植物相关的并发症的发生频率是否存在差异?(3)两种技术在移植物源性复发方面是否存在差异?(4)在接受体外照射或冷冻处理的自体移植物中,无失败的移植物、肢体和整体存活率是否存在差异?
在研究期间,我们共治疗了 333 例高级别骨肉瘤患者。排除了 169 例患者。总的来说,164 例患者中有 79 例接受了体外照射处理的回收自体移植物,而另外 85 例接受了冷冻处理的自体移植物。体外照射组的平均随访时间为 82±54 个月,冷冻自体移植物组为 70±25 个月,1 例患者失访。并发症和移植物失败(需要对原发性移植物进行修复)通过适应国际肢体协会(ISOLS)系统进行评估,该系统经过改良,包括生物和可扩张重建。主要研究终点是每组患者在术后 6、9、12 和 18 个月达到影像学愈合的比例,以及达到 ISOLS 分级为良好或较好的宿主移植物融合的比例。采用累积发生率回归模型分析移植物失败和肢体截肢的 5 年生存率数据,采用 Kaplan-Meier 函数检验两种技术的 5 年总体生存率。
根据现有数据,两组患者在术后 6、9、12 和 18 个月时达到愈合的累积比例无差异。影像学评估显示,比较标准的平均评分无差异。然而,在软骨下骨亚标准中,更多接受冷冻处理的自体移植物的患者具有更高的评分(p=0.03)。在软组织失败(1B 型)、非愈合(2B 型)、结构失败(3A 型和 3B 型)或感染(4A 型和 4B 型)方面,体外照射和冷冻自体移植物导致的并发症无差异。两组均未发现移植物源性肿瘤复发,两组间软组织起源的 5A 型肿瘤进展无差异(比值比,0.8;95%CI,0.3-2.1;p=0.7)。两组在移植物失败和肢体截肢的累积发生率方面均无差异。体外照射和冷冻自体移植物的 5 年总体生存率分别为 83%和 84%(p=0.69)。体外照射组在术后 50 至 100 个月时生存率下降。
在本研究中,我们将 ISOLS 评估移植物介导的肿瘤进展的标准分为宿主或移植物来源的并发症(5B 和 5C 型)。根据现有数据,来自照射或冷冻处理的自体移植物的肿瘤复发发生率无差异。比较两组 10 年生存率的持续评估将有助于阐明 100 个月后可能发现的差异。
III,治疗研究。